T he lysosome, which serves as the cell's recycling centre, can mediate the hydrolase-based degradation of a variety of biomaterials, including proteins, lipids and membranes 1 . Most lysosomal storage diseases (LSDs), of which more than 50 are known, are due to the defective activities of specific lysosomal enzymes, which result in the lysosomal accumulation of specific substrates 2 . For instance, in Niemann-Pick (NP) type A and B diseases (NPA and NPB), sphingomyelins (SMs) accumulate in lysosomes due to insufficient activity of acid SMase (aSMase) (Supplementary Fig. S1 ) 3 ; similarly, insufficient aSMase activity and SM accumulation occur in NP type C (NPC), where the genetic defect occurs in components of an intracellular cholesterol/lipid trafficking pathway 3, 4 . Interestingly, regardless of the nature of the primary undigested metabolites, common cellular defects are seen in a spectrum of LSDs 5 . For example, defects in lipid trafficking (the exit of lipids from the late endosome and lysosome) and autophagome-lysosome fusion are commonly observed in almost all sphingolipidoses, including NPA, NPB and NPC 2, 6 . In addition, altered Ca 2 + and Fe 2 + homoeostasis are also common factors in these LSDs 2, 5, 7 . Thus, it is likely that the common trafficking machinery is impaired in LSDs with unrelated origins or primary defects. One intriguing hypothesis is that the primary accumulated materials cause a sort of 'lysosome stress, ' which impairs common biochemical and/or signalling pathways in the lysosome, similar to the way unfolded proteins cause 'ER stress' to trigger an 'unfolded protein response' 2, 5 .
Cells that lack mucolipin transient receptor potential (TRP) channel 1 (TRPML1) exhibit lysosomal defects similar to those seen in NP cells: defective autophagosome-lysosome fusion or lysosome reformation, abnormal lipid trafficking and altered Ca 2 + and Fe 2 + homoeostasis [8] [9] [10] [11] [12] [13] [14] [15] . Furthermore, mutations in the human Trpml1 gene cause mucolipidosis type IV (ML4) LSD, which exhibits membrane trafficking defects and excessive lysosomal storage [16] [17] [18] . TRPML1 is a ubiquitously expressed Fe 2 + and Ca 2 + dually permeable channel predominantly localized in late endosomes and lysosomes (LELs) 11, 13, [19] [20] [21] . TRPML1 is specifically activated by phosphatidylinositol 3,5-bisphosphate (PI(3,5)P 2 ), an LEL-localized low-abundance phosphoinositide 14 . In addition, both TRPML1-lacking and PI(3,5)P 2 -deficient cells exhibit defects in LEL-to-Golgi retrograde trafficking and autophagosome-lysosome fusion 8, 15, 22, 23 , suggesting that the TRPML1-PI(3,5)P 2 system represents a common signalling pathway essential for late endocytic trafficking.
Owing to the high degree of similarity in lysosomal defects, we hypothesized that TRPML1-PI(3,5)P 2 signalling is compromised in NPs and many other LSDs. In this study, we measured lysosomal Ca 2 + release with lysosome-targeted, genetically encoded Ca 2 + indicators and found that TRPML1-mediated lysosomal Ca 2 + release was compromised in NPC and NPA cells. Patch-clamp analyses demonstrated that TRPML1 channel activity was inhibited by micromolar concentrations of SMs, but potentiated by SM-hydrolysing enzyme SMases. In NPC cells, increasing TRPML1's expression or activity was found to be capable of correcting the trafficking defects and decrease cholesterol accumulation. We conclude that SMs are negative regulators of TRPML1 channels under physiological conditions, and that abnormal accumulation of SMs in the lysosome lumen blocks Ca 2 + -dependent membrane trafficking by directly inhibiting TRPML1.
Results

Identification of a potent synthetic agonist for TRPML1.
A recent high-throughput screen identified 15 small-molecule chemical compounds (SF compounds) that can activate recombinant surfaceexpressed TRPML3 21 . TRPML1 is primarily localized on the membranes of LELs 13 . Using whole-endolysosome patch-clamp recordings 11, 14 , we found that several SF compounds also weakly activated whole-endolysosome TRPML1-mediated currents (I TRPML1 or I ML1 , data not shown). In HEK293T cells transfected with Fig. 1a,b) , and activated small but significant inwardly rectifying whole-cell currents (I ML1 − 4A ; Fig. 1d ).
By conducting a Fura-2-based low-throughput screen for more potent TRPML1 agonists, we identified a SF-51-related compound (Fig. 1c for the chemical structures; Mucolipin Synthetic Agonist 1 or ML-SA1) that could induce significant [Ca 2 + ] cyt increases in HEK293 cells stably or transiently expressing ML1-4A (Fig. 1a) . In electrophysiological assays, ML-SA1 robustly activated whole-cell I ML1 − 4A (Fig. 1d) and whole-endolysosome I ML1 (Fig. 1e) . ML-SA1 also activated whole-cell I TRPML2 and I TRPML3 , but not six other related channels (Supplementary Fig. S2 ). ML-SA1 (10 µM) activation of whole-endolysosome I ML1 was comparable to the effect of the endogenous TRPML agonist PI(3,5)P 2 (1 µM; Fig. 1e ), and these agonists were synergistic with each other (Fig. 1f) . ML-SA1 activated an endogenous whole-endolysosome TRPML-like current (I ML − L ) in all mammalian cell types that we investigated, including Chinese Hamster Ovary (CHO) (Fig. 1g) , Cos-1, HEK293, skeletal muscle, pancreatic β and macrophage cells (Fig. 1h) . ML-SA1 activated whole-endolysosome I ML − L in wild-type (WT; ML1 + / + ), but not ML4 (ML1 − / − ) human fibroblasts (Fig. 1i) , suggesting that although ML-SA1 targets all three TRPMLs, the expression levels of TRPML2 and TRPML3 are very low, and TRPML1 is the predominant lysosomal TRPML channel in this cell type. Thus, we have identified a reasonably specific and potent agonist that can be a useful chemical tool for studying the functions of TRPMLs, especially TRPML1.
A lysosome-targeted genetically encoded Ca 2 + indicator. To measure lysosomal Ca 2 + release in intact cells, we engineered GCaMP3, a single-wavelength genetically encoded Ca 2 + indicator 24 , to the cytoplasmic amino terminus of TRPML1 (Fig. 2a) . When transfected into HEK293T, CHO or Cos-1 cell lines, GCaMP3-TRPML1 (GCaMP3-ML1) was mainly localized in the Lamp-1 and LysoTracker-positive compartments, that is, LEL (Fig. 2b,c) . To determine the specificity of the GCaMP3-ML1 fluorescence signal, we tested a variety of Ca 2 + release reagents and found that GCaMP3 fluorescence (F 470 ) responded preferentially and reliably to lysosome-acting Ca 2 + -mobilization reagents (∆F/F 0 = 0.2-1), including glycyl-l-phenylalanine 2-naphthylamide (GPN, a Cathepsin C substrate that induces osmotic lysis of lysosomes; Fig. 2d ) and bafilomycin A1 (Baf-A1, a V-ATPase inhibitor) 25 . In a subset of cells, GCaMP3 also responded to large (∆F/F 0 > 2) Ca 2 + increases triggered by thapsigargin (targeting the endoplasmic recticulum (ER) Ca 2 + store; Fig. 2d ), which may presumably spread to close proximity of lysosomes. In the majority of the cells, however, TG failed to significantly increase GCaMP3 fluorescence (Fig. 2d) , suggesting that small ER Ca 2 + release was not detected by GCaMP3-ML1. Taken together, GCaMP3-ML1 readily and preferentially detects juxta-lysosomal Ca 2 + increases.
In GCaMP3-ML1-transfected CHO (Fig. 3a,b ), HEK293T and Cos-1 cell lines, application of ML-SA1 (20 µM) induced rapid increases in GCaMP3 fluorescence (∆F/F 0 = 0.45 ± 0.05, n = 77 cells; Fig. 3a,k) in the presence of low external Ca 2 + (nominally free Ca 2 + + 1 mM EGTA; free Ca 2 + estimated to be < 10 nM). By contrast, no significant increase in GCaMP3 fluorescence (∆F/F 0 = 0.03 ± 0.01, n = 32 cells; Fig. 3c,d and k) was observed in cells transfected with a plasmid carrying GCaMP3 fused to a nonconducting pore mutant of TRPML1 8, 14 (GCaMP3-ML1-KK). Both GPN and Baf-A1 largely abolished ML-SA1-induced Ca 2 + responses ( Fig. 3e-k) . By contrast, ML-SA1-induced Ca 2 + response was mostly intact in TG-treated cells (Fig. 3k) . Collectively, these results suggest that ML-SA1 activated endolysosomal TRPML1 to induce Ca 2 + release from lysosomes. Thus, we have established a robust Ca 2 + imaging assay to measure TRPML1-mediated lysosomal Ca 2 + release.
Reduced TRPML1-mediated lysosomal Ca 2 + release in NPC cells. Next, we investigated whether TRPML1-mediated lysosomal Ca 2 + release is altered in NP cells. We chose an easy-to-transfect cellular model of NPC, NPC (NPC1 − / − ) CHO cells, which exhibit all the hallmark features of NPC disease 26, 27 . WT CHO cells transfected with GCaMP3-ML1 exhibited large TRPML1-mediated lysosomal Ca 2 + release (Fig. 4a,l) . In contrast, NPC CHO cells exhibited much smaller TRPML1-mediated Ca 2 + release with a ~75% reduction compared with WT controls (Fig. 4b,l) . GCaMP3-ML1 was still mainly colocalized with Lamp-1 in NPC cells (Fig. 4c) . In addition, the expression levels of GCaMP3-ML1, as estimated from the maximal fluorescence intensity induced by ionomycin, were comparable for WT and NPC cells (Fig. 4d) . A previous study reported that lysosomal Ca 2 + stores are compromised in NPC cells 25 . However, we found that GPN-induced GCaMP3-ML1 increases were comparable for WT and NPC cells (Fig. 4e) . Likewise, GPN-induced and NH 4 Cl-induced Fura-2 responses were also comparable in nontransfected WT and NPC cells (Fig. 4f,g ). Furthermore, TRPML1-mediated, but not GPN-induced lysosomal Ca 2 + release, was also reduced in GCaMP3-transfected NPC human fibroblasts compared with WT cells (Fig. 4h) . Collectively, these results suggest that TRPML1-mediated lysosomal Ca 2 + release is selectively reduced in NPC cells.
NPC-like cellular phenotypes can be pharmacologically induced with a small-molecule drug U18666A 28 . After incubating GCaMP3-ML1-transfected WT CHO cells with U18666A (2 µg ml − 1 ) for 16-20 h, cells exhibited significant increases in cholesterol level as detected by filipin staining 4 (Fig. 4i) , and sphingomyelin (SM) Enlarged vacuoles/endolysosomes were isolated from vacuolin-treated HEK293 cells stably expressing mL1-4A. mL-sA1 and PI(3,5)P 2 were applied to the cytosolic sides of the isolated vacuoles. The pipette (luminal) solution was a standard external (Tyrode's) solution adjusted to pH 4.6; the bath (internal/cytoplasmic) solution was a K + -based solution (140 mm K + -gluconate). note that the inward current indicates cations flowing out of the endolysosome. (f) synergistic activation of whole-endolysosome I mL1 by mL-sA1 and PI(3,5)P 2 in human fibroblasts. I mL1 was activated by PI(3,5)P 2 (1 µm) and mL-sA1 (10 µm); coapplication of PI(3,5)P 2 and mL-sA1 further increased I mL1 . (g) mL-sA1 activated endogenous whole-endolysosome mL-like currents (I mL − L ) in CHo cells. (h) mL-sA1 activated whole-endolysosome I mL − L in mouse primary macrophages. (i) mL-sA1 activated whole-endolysosome I mL1 in WT (mL1 + / + ), but not mL4 (mL1 − / − ), human fibroblasts. For panels a and b, the responses were averaged for 20-40 cells from one representative experiment; dara are presented as the mean±s.e.m.
level as detected by lysenin staining (Fig. 4j ). U18666A-treated cells exhibited a ~70% reduction in TRPML1-mediated lysosomal Ca 2 + release ( Fig. 4k,l) . Conversely, drug treatment failed to result in noticeable changes in GPN-induced GCaMP3 responses (Fig. 4e ) or Fura-2 Ca 2 + responses (Fig. 4f ). Taken together, these results suggest a specific reduction of TRPML1-mediated lysosomal Ca 2 + release in pharmacologically induced NPC cells. We next investigated the effect of NPC on endogenous Ca 2 + release using Fura-2 Ca 2 + imaging. In WT CHO cells, small but significant Ca 2 + increases were seen upon application of 100 µM ML-SA1 in low external Ca 2 + (∆Fura-2 = 0.08 ± 0.01, n = 89; Fig. 4m,o) . In contrast, in NPC CHO cells, ML-SA1 failed to induce significant Ca 2 + responses (∆Fura-2 = 0.01 ± 0.002, n = 61; Fig. 4n,o) . Cyclodextrin, a polysaccharide that reportedly alleviates NPC cellular phenotypes 4 , was found to partially restore ML-SA1-induced lysosomal Ca 2 + release ( Supplementary Fig. S3 ). Finally, NPC1 − / − mouse macrophages, one of the major cell types affected in NPC 3 , also exhibited a significant reduction in ML-SA1-induced lysosomal Ca 2 + release compared with WT cells ( Fig. 4o and Supplementary Fig. S4 ). The ML-SA1-induced lysosomal Ca 2 + responses are most likely mediated by TRPML1, as demonstrated by the lack of response in ML1 − / − macrophages ( Fig. 4o and Supplementary  Fig. S4 ). Collectively, the reduction in TRPML1-mediated lysosomal Ca 2 + release may be a general feature of most NPC cell types.
Reduced TRPML1-mediated currents in NPC cell lysosomes. We next investigated the effect of NPC on whole-endolysosome I ML1 in human fibroblasts. Compared with WT fibroblasts (Fig. 5a,c) , much smaller ML-SA1-activated I ML1 was seen in NPC fibroblasts at three different concentrations of ML-SA1 (Fig, 5b,c) . On average, wholeendolysosome I ML1 activated by 25 µM ML-SA1 was 75 ± 25 pA/pF (n = 8) for NPC cells, a ~70% reduction from the values observed for WT cells (442 ± 150 pA/pF; n = 6). Notably, the messenger RNA expression levels of TRPML1-3 were not decreased in NPC cells (Fig, 5d) . These results suggest that a reduction of whole-endolysosome I ML1 accounts for the reduced TRPML1-mediated Ca 2 + release observed in NPC cells.
Inhibition of TRPML1 by SMs. The reduced TRPML1-mediated lysosomal Ca 2 + release and I ML1 in the presence of normal TRPML1 expression in NPC cells suggest tonic inhibition of TRPML1 by cytoplasmic and/or luminal factors. One possibility is that lipids accumulated in NPC lysosomes, such as cholesterol, SM, sphingosine and glycosphingolipids 4, 29 , might directly inhibit TRPML1. To test this possibility, we performed whole-cell recordings in ML1-4A-expressing HEK293T cells. Under this configuration, the extracellular side is analogous to the luminal side ( Supplementary Fig. S1 ), making it possible to study the effects of luminal lipids on I ML1 − 4A . SMs, but not cholesterol or glycosphingolipids (data not shown), acutely inhibited SF-51- (Fig, 6a,d ) or ML-SA1-activated I ML1 − 4A . In contrast, SMs failed to inhibit I ML1 − Va, a gain-of-function mutation that locks TRPML1 in the open state 13 (Fig. 6b,d ). SMs can be hydrolysed into ceramide and phosphocholine by SMase (Supplementary Fig. S1 ). No significant inhibition was seen with ceramide ( Fig. 6c,d ) or phosphocholine (Fig. 6d) . Sphingosine, a hydrolysed product of ceramide, potentiated I ML1 − 4A (Fig. 6e) .
The robust inhibition of I ML1 − 4A by SMs, but not ceramide or phosphocholine, suggests that the activity of SMase may regulate I ML1 − 4A . Indeed, bath application of SMases, but not heat-inactivated enzymes, significantly potentiated SF-51-activated I ML1 − 4A (Fig. 6f-k) , with the potentiation being more dramatic at acidic extracellular (luminal) pH than at neutral pH (Fig. 6k) .
SM accumulation reduces TRPML1-mediated Ca 2 + release. The results presented above suggest that SM-mediated inhibition underlies NPC-mediated reduction in TRPML1-mediated lysosomal Ca 2 + release. Consistent with this, in fibroblasts derived from NPA patients, which completely lack the activity of aSMase 3 , TRPML1-mediated, but not GPN-induced, lysosomal Ca 2 + release (Fig. 7a-c) was significantly reduced. To further test this hypothesis, we induced lysosomal SM accumulation by incubating cells with desipramine and fluoxetine for 2-4 h, which cause proteolytic degradation of aSMase 30, 31 . Compared with non-treated cells, TRPML1-mediated lysosomal Ca 2 + release was dramatically reduced in desipramine/ fluoxetine-treated CHO cells, and the reduction was abolished in the presence of a protease inhibitor leupeptin 30, 31 ( Fig. 7d-g ). Taken together, these results suggest that SM inhibition of TRPML1 underlies NPA-or NPC-mediated attenuation of TRPML1-mediated lysosomal Ca 2 + release.
TRPML1 regulates lysosomal lipid and cholesterol trafficking.
Human NPC, NPA and NPB fibroblasts exhibit defects in LELto-Golgi trafficking of lipids and proteins 6, 27 . Consistent with this, BODIPY-LacCer, a fluorescent analogue of lactosylceramide that is localized in the Golgi apparatus of WT cells after a pulse-chase period 32 , was predominantly localized in the LEL-like compartments of NPC1 − / − mouse macrophages (Fig. 8a) . Owing to the established roles of PI(3,5)P 2 /TRPML1/Ca 2 + in LEL-to-Golgi lipid trafficking 15 , it is possible that the trafficking defects seen in NP cells For panels d, e, f, g, h, k, l and o, the results were averaged for 40-100 cells from at least three independent experiments; data are presented as the mean ± s.e.m. statistical comparisons were made using analysis of variance: *P < 0.05.
are due to the aforementioned attenuated TRPML1-mediated lysosomal Ca 2 + release. If so, one would expect that boosting TRPML1 activity may correct the trafficking defects. Indeed, more than 60% of ML-SA1-treated NPC macrophages exhibited a Golgi-like pattern of LacCer staining, suggestive of a significant restoration in LEL-to-Golgi transport (Fig. 8a) . In NPC1 − / − mouse macrophages and TRPML1-transfected NPC CHO cells, the puncta number of LacCer staining, that reflects the function of LEL-to-Golgi transport, was significantly reduced in the presence of ML-SA1 ( Fig. 8b and Supplementary Fig. S5 ). Collectively, these results suggest that increasing TRPML1's channel activity may restore the trafficking defects in NPC cells, and that TRPML1 deregulation is a pathogenic mechanism underlying lipid trafficking defects in NP cells. NPC cells accumulate cholesterol, as demonstrated by elevated filipin staining 25 . However, in U18666A-treated CHO cells, ML-SA1 induced a significant reduction in filipin staining in TRPML1, but not TRPML1-KK-transfected cells (Fig. 8c,d) . Likewise, in TRPML1-transfected NPC CHO cells, a significant reduction of filipin staining was also seen in the presence of ML-SA1 (Supplementary Fig. S5 ). Reduction of filipin staining was also seen in aSMase- (Fig. 8e,f) and TRPML1 Va -transfected NPC CHO cells (Fig. 8g,h ). These results suggest that increased TRPML1 activity may reduce cholesterol accumulation in NPC cells.
Discussion
We used a lysosome-targeted GCaMP3-based Ca 2 + imaging method to demonstrate that TRPML1-mediated lysosomal Ca 2 + release, but not the lysosomal Ca 2 + store as has been reported previously 25 , is selectively compromised in NPC and NPA cells. SM, a sphingolipid that is known to accumulate in all three types of NP cells 4 , inhibits TRPML1. Pharmacologically induced SM accumulation significantly reduces TRPML1-mediated lysosomal Ca 2 + release. Conversely, increasing TRPML1's expression or activity is sufficient to correct the trafficking defects and reduce cholesterol accumulation in NPC cells. Collectively, our work provides a feedback mechanism for luminal lipids to control lipid efflux from the lysosome, as well as a pathogenic cause for the secondary lysosome storage present in many LSDs.
SMs are present on the outer leaflet of the plasma membrane 33 , suggesting that SM inhibition of TRPML1 might serve as a physiological mechanism to prevent this lysosome channel from being active at the wrong subcellular location, that is, the plasma membrane. For normal cells, SMs in the lysosome would be rapidly degraded by aSMase activity 33 . In NP cells, however, SMs accumulate in the lumen and limited lysosomal membranes ( Supplementary  Fig. S1 ). Although the primary storage is likely to be cholesterol, NPC cells are found to have a much lower level of aSMase activity, and a restoration of aSMase activity could revert cholesterol accumulation 34 . It is not known whether the level of SM is perturbed in other sphingolipidoses. However, rather than absolute SM levels, the relative localization (plasma membrane versus lysosome) is the factor critical for lysosomal Ca 2 + release. In addition, other offending metabolites might also inhibit TRPML1, and/or PI(3,5)P 2 -metabolizing enzymes. Thus, impaired Ca 2 + release might be a common pathogenic mechanism for many LSDs. Although TRPML1 is the dominant lysosomal TRPML channel in most cell types, in other cell types where TRPML2 and TRPML3 are more abundantly expressed 13 , our proposed SM-mediated inhibitory mechanism may also be applied to TRPML2/3, causing lysosomal trafficking defects. Finally, SM and cholesterol accumulation might also contribute to NP phenotypes via mechanisms unrelated to lysosomal trafficking and TRPMLs 3 .
LEL-to-Golgi trafficking defects are seen in PI(3,5)P 2 -deficient cells 22 , ML4 fibroblasts 15, 35 and NP fibroblasts, as well as fibroblasts from several other sphingolipid LSDs 6,36 . Our results suggest that reduced TRPML1-mediated lysosomal Ca 2 + release directly causes trafficking defects. We previously reported that impaired Fe 2 + homoeostasis facilitates the formation of autofluorescent lipofuscin in ML4 cells 11 . Interestingly, lipofuscin formation is also increased in NPC cells (Supplementary Fig. S6 ). For most LSDs, impaired lysosomal degradation due to a lack of hydrolytic enzymes leads to trafficking defects and lysosome storage. However, lysosome storage can in turn affect lysosomal degradation and membrane trafficking, which results in a positive feedback loop and a vicious cycle 2 . Our work suggests a novel concept that lysosome enhancement by manipulating TRPML1 to speed membrane trafficking may break the vicious cycle, providing a novel therapeutic approach for NPs and many other LSDs.
Methods
Molecular biology and biochemistry. The GCaMP3-ML1 construct was made by inserting the full-length GCaMP3 sequence 24 between the HindIII and BamHI sites of a pcDNA6 plasmid that contains the mouse TRPML1 complementary DNA at the XhoI site. TRPML1-L 15 L/AA-L 577 L/AA (abbreviated as ML1-4A) and the TRPML1 non-conducting pore mutant (D471K/D472K; abbreviated as ML1-KK) were constructed using a site-directed mutagenesis kit (Qiagen). All constructs were confirmed by sequencing, and protein expression was verified by western blot. CHO, HEK293T, Cos-1 and human fibroblast cells were transiently transfected with GCaMP3-ML1 for electrophysiology, Ca 2 + imaging and confocal imaging. PCR primers used for real-time quantitative PCR analysis of TRPML expression in human fibroblasts and mouse macrophages are as follows:
Human TRPML1: F, 5′-CGGATGACACCTTCGCAGCCTAC-3′; R, 5′-ACGCATACCGGCCCAGTGACAC-3′ Human TRPML2: F, 5′-GGTCACCACACAGCTTGTTCGT-3′; R, 5′-TGATGATACTGATTAATAGCA-3′ Human TRPML3: F, 5′-CCAGAAATTGAAACTGAGTGTT-3′; R, 5′-ATGTTATAGTCAGAGTAAAGTC-3′ Mouse TRPML1: F, 5′-AAACACCCCAGTGTCTCCAG-3′; R, 5′-GAATGACACCGACCCAGACT-3′ n=8) . statistical comparisons were made using analysis of variance: *P < 0.05.
Preparation and culture of mouse macrophages. Bone marrow cells from femurs and tibias were harvested and cultured in macrophage differentiation medium (RPMI-1640 medium with 10% fetal bovine serum (FBS) and 100 U ml − 1 recombinant colon stimulating factor from PeproTech, Rocky Hill, NJ, USA). After 7 days in culture at 37 °C with 5% CO 2 , the adherent cells ( > 95% are expected to be macrophages) were harvested for assays 38 . The potentiation effect of smase was more dramatic at pH 4.6, but abolished by heat inactivation of the enzyme activity. HI-smase: heat-inactivated smase. For panels d and k, data are presented as the mean ± s.e.m.; the n numbers are in parentheses. statistical comparisons were made using analysis of variance: *P < 0.05. Fura-2 Ca 2 + imaging. Cells were loaded with 5 µM Fura-2 AM in the culture medium at 37 °C for 60 min. Fluorescence was recorded at different excitation wavelengths using an EasyRatioPro system (PTI). Fura-2 ratios (F 340 /F 380 ) were used to monitor changes in intracellular [Ca 2 + ] upon stimulation. GPN (200-400 µM, a lysosome-disrupting agent) and Baf-A1 (500 nM, a V-ATPase inhibitor) were used as positive controls to induce Ca 2 + release from lysosome and acidic stores, respectively 39 . Ionomycin (1 µM) was added at the conclusion of all experiments to induce a maximal response for comparison. For endogenous lysosomal Ca 2 + release measurement, Ca 2 + imaging was carried out within 0.5-3 h after plating and when cells still exhibited a round morphology.
GCaMP3 Ca 2 + imaging. At 18-24 h after transfection with GCaMP3-ML1, CHO or human fibroblast cells were trypsinized and plated onto glass coverslips. Most experiments were carried out within 0.5-3 h after plating when cells still exhibited a round morphology. The fluorescence intensity at 470 nm (F 470 ) was monitored using the EasyRatioPro system. Lysosomal Ca 2 + release was measured under a 'low' external Ca 2 + solution, which contained 145 mM NaCl, 5 mM KCl, 3 mM MgCl 2 , 10 mM glucose, 1 mM EGTA and 20 mM HEPES (pH 7.4). Ca 2 + concentration in the nominally free Ca 2 + solution is estimated to be 1-10 µM. With 1 mM EGTA, the free Ca 2 + concentration is estimated to be < 10 nM based on the Maxchelator software (http://maxchelator.stanford.edu/).
LacCer-BODIPY trafficking. Cells for the Lactosylceramide (LacCer)-BODIPY uptake experiment were grown on glass coverslips and incubated with 5 µM bovine serum albumin-complexed LacCer in 'Tyrode' solution for 45 min at room temperature. Cells were then washed twice with PBS and incubated with normal DMEM/F12 medium containing 10% FBS at 37 °C for 1 h. For the correction experiments, NPC1 − / − macrophages were pretreated with ML-SA1 (10 µM) for with Fura-2 ratios; 100 µm mL-sA1) in CHo cells. For panels c, f and g, the results were averaged for 40-100 cells from at least three independent experiments; data are presented as the mean ± s.e.m. statistical comparisons were made using analysis of variance: *P < 0.05. , f and h, the results were averaged for multiple randomly taken micrographs from at least three independent experiments. Data are presented as the mean ± s.e.m. statistical comparisons were made using analysis of variance: *P < 0.05.
